GIP
PRTK

Granite Investment Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Granite Investment Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-31,688
Closed -$610K – 316
2017
Q1 		$610K Sell
31,688
-39,889
-56% -$628K 0.04% 270
2016
Q4 		$1.1M Sell
71,577
-6,624
-8% -$86K 0.08% 223
2016
Q3 		$1.02M Buy
78,201
+30,425
+64% +$403K 0.08% 238
2016
Q2 		$665K Buy
+47,776
New +$703K 0.05% 259

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Granite Investment Partners's PRTK Position: Q2 2017 in Review

Granite Investment Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2017, closing a stake of 31,688 shares — an estimated $610K sold.

Granite Investment Partners first reported a position in PRTK in Q2 2016 and held it in 4 quarters. The position peaked at $1.1M in Q4 2016. 119 funds tracked by Wall St. Rank hold PRTK as of Q2 2017.

  • Granite Investment Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Granite Investment Partners sold 31,688 Paratek Pharmaceuticals, Inc. shares in Q2 2017, an estimated $610K.
  • Granite Investment Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 4 quarters.
  • Granite Investment Partners's Paratek Pharmaceuticals, Inc. position peaked at $1.1M in Q4 2016.
  • 119 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2017.

Based on Granite Investment Partners's 13F filing for Q2 2017, filed 2 Aug 2017.